




TUMOUR AVATAR in Personalised Medicine

3D PATIENT-DERIVED ORGANOID "ONCO-PDO" is able to recapitulate the cancer heterogeneity of tumours found 'in-vivo'





3D MACROPOROUS SCAFFOLDING allows multiple different cell types and cell-to-cell interactions

PHYSIOLOGICAL PATIENT-DERIVED TUMOUR ORGANOID CELLS tumor organoids are grown within scaffolds

"Personalised Medicine"

is a medical model that proposes the **customisation of healthcare**, with medical decisions, practices and/or products being **tailored to the individual patient ("patient-specific")**

Onco-PDO ANALYTICS TESTING



VALUE PROPOSITION


Onco-PDO is potentially optimised to:

- have consistent organoid formation in multiple cancer tumours (biobank)
- functionally, cellularly, and molecularly similar to cancer tumours residing in body (physiological relevant)
- improve preclinical testing and pharmacological compound or drug validation by assessing efficacy and safety (high-throughput screening)
- obtain drug efficacy and safety data prior to administering drugs (medical intervention)
- address inter-individual human population variability (patient-specific response)




TUMOUR AVATAR **in** Personalised Medicine

3D PATIENT-DERIVED
ORGANOID
"ONCO-PDO"
is able to recapitulate the cancer
heterogeneity of tumours found 'in-vivo'



3D MACROPOROUS
SCAFFOLDING
allows multiple different cell types
and cell-to-cell interactions





PHYSIOLOGICAL
PATIENT-DERIVED
TUMOUR
ORGANOID CELLS
tumor organoids are grown within
scaffolds

"Personalised Medicine"

is a medical model that proposes the **customisation of healthcare**, with medical decisions, practices and/or products being **tailored to the individual patient ("patient-specific")**

Onco-PDO ANALYTICS TESTING





VALUE PROPOSITION

Onco-PDO is potentially optimised to:

- have consistent organoid formation in multiple cancer tumours (biobank)
- functionally, cellularly, and molecularly similar to cancer tumours residing in body (physiological relevant)
- improve preclinical testing and pharmacological compound or drug validation by assessing efficacy and safety (high-throughput screening)
- obtain drug efficacy and safety data prior to administering drugs (medical intervention)
- address inter-individual human population variability (patient-specific response)

